O'Donnell-Luria-Rodan syndrome: description of a second multinational cohort and refinement of the phenotypic spectrum.


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
07 2022
Historique:
received: 20 11 2020
accepted: 02 07 2021
pubmed: 30 7 2021
medline: 30 6 2022
entrez: 29 7 2021
Statut: ppublish

Résumé

O'Donnell-Luria-Rodan syndrome (ODLURO) is an autosomal-dominant neurodevelopmental disorder caused by pathogenic, mostly truncating variants in Affected individuals were ascertained at paediatric and genetic centres in various countries by diagnostic chromosome microarray or exome/genome sequencing. Patients were collected into a case cohort and were systematically phenotyped where possible. We report 18 additional patients from 17 families with genetically confirmed ODLURO. We identified 15 different heterozygous likely pathogenic or pathogenic sequence variants (14 novel) and two partial microdeletions of Our study, bringing the total of known patients with ODLURO to more than 60 within 2 years of the first publication, suggests an unexpectedly high relative frequency of this syndrome worldwide. It seems likely that ODLURO, although just recently described, is among the more common single-gene aetiologies of neurodevelopmental delay and ASD. We present the second systematic case series of patients with ODLURO, further refining the mutational and phenotypic spectrum of this not-so-rare syndrome.

Sections du résumé

BACKGROUND
O'Donnell-Luria-Rodan syndrome (ODLURO) is an autosomal-dominant neurodevelopmental disorder caused by pathogenic, mostly truncating variants in
METHODS
Affected individuals were ascertained at paediatric and genetic centres in various countries by diagnostic chromosome microarray or exome/genome sequencing. Patients were collected into a case cohort and were systematically phenotyped where possible.
RESULTS
We report 18 additional patients from 17 families with genetically confirmed ODLURO. We identified 15 different heterozygous likely pathogenic or pathogenic sequence variants (14 novel) and two partial microdeletions of
CONCLUSION
Our study, bringing the total of known patients with ODLURO to more than 60 within 2 years of the first publication, suggests an unexpectedly high relative frequency of this syndrome worldwide. It seems likely that ODLURO, although just recently described, is among the more common single-gene aetiologies of neurodevelopmental delay and ASD. We present the second systematic case series of patients with ODLURO, further refining the mutational and phenotypic spectrum of this not-so-rare syndrome.

Identifiants

pubmed: 34321323
pii: jmedgenet-2020-107470
doi: 10.1136/jmedgenet-2020-107470
pmc: PMC10256139
mid: NIHMS1902865
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

697-705

Subventions

Organisme : NHGRI NIH HHS
ID : R01 HG009141
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS058721
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Front Pediatr. 2021 Feb 18;9:641841
pubmed: 33681112
J Hum Genet. 2014 Oct;59(10):581-3
pubmed: 25102098
Mol Psychiatry. 2020 Oct;25(10):2220-2236
pubmed: 32034290
Cell. 2019 Jan 24;176(3):535-548.e24
pubmed: 30661751
Nat Genet. 1999 Oct;23(2):185-8
pubmed: 10508514
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Neurosci. 2007 Oct 17;27(42):11254-62
pubmed: 17942719
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
J Med Genet. 2016 May;53(5):330-7
pubmed: 26769062
Hum Mol Genet. 2016 Mar 1;25(5):927-35
pubmed: 26740553
Science. 2020 Mar 6;367(6482):
pubmed: 32139519
Mol Autism. 2018 Dec 13;9:64
pubmed: 30564305
Cell Rep. 2014 Oct 9;9(1):16-23
pubmed: 25284784
Curr Psychiatry Rep. 2018 Mar 5;20(2):9
pubmed: 29504047
Nature. 2011 Oct 26;478(7370):483-9
pubmed: 22031440
Genet Med. 2020 Feb;22(2):245-257
pubmed: 31690835
J Comput Biol. 2004;11(2-3):377-94
pubmed: 15285897
Am J Med Genet A. 2017 Aug;173(8):2132-2138
pubmed: 28574232
Neuropediatrics. 2021 Apr;52(2):98-104
pubmed: 33111303
Cell. 2014 Jul 17;158(2):263-276
pubmed: 24998929
Epigenetics. 2009 Jan;4(1):47-53
pubmed: 19029819
Radiol Med. 2021 Feb;126(2):316-322
pubmed: 32691224
Mol Cell Probes. 2019 Jun;45:84-88
pubmed: 30914295
Nat Commun. 2016 Nov 08;7:13316
pubmed: 27824329
Nat Cell Biol. 2007 Dec;9(12):1401-12
pubmed: 17994010
Am J Med Genet C Semin Med Genet. 2019 Dec;181(4):557-564
pubmed: 31721432
Cell Mol Life Sci. 2017 Jul;74(13):2333-2344
pubmed: 28188343
Hum Mutat. 2018 Nov;39(11):1593-1613
pubmed: 30311386
Med Genet. 2018;30(3):318-322
pubmed: 30459487
Am J Hum Genet. 2013 Feb 7;92(2):221-37
pubmed: 23375656
Med Genet. 2018;30(3):323-327
pubmed: 30459488
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Hum Genet. 2020 Apr;139(4):499-512
pubmed: 31980904
Neuron. 2012 Apr 26;74(2):285-99
pubmed: 22542183
J Pediatr Neurosci. 2015 Oct-Dec;10(4):304-7
pubmed: 26962332
Am J Hum Genet. 2019 Jun 6;104(6):1210-1222
pubmed: 31079897
PLoS One. 2013 Oct 09;8(10):e77020
pubmed: 24130829
Am J Hum Genet. 2019 Dec 5;105(6):1274-1285
pubmed: 31785789
Prog Brain Res. 2010;186:77-95
pubmed: 21094887
Cell. 2020 Feb 6;180(3):568-584.e23
pubmed: 31981491
Clin Genet. 2019 Jul;96(1):72-84
pubmed: 31001818

Auteurs

Clara Velmans (C)

Institute of Human Genetics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.

Anne H O'Donnell-Luria (AH)

Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.

Emanuela Argilli (E)

Brain Development Research Program, Department of Neurology, University of California San Francisco Division of Hospital Medicine, San Francisco, California, USA.

Frederic Tran Mau-Them (F)

UFR Des Sciences de Santé, INSERM UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Université de Bourgogne, Dijon, Bourgogne, France.
Unité Fonctionnelle d'Innovation diagnostique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Antonio Vitobello (A)

UFR Des Sciences de Santé, INSERM UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Université de Bourgogne, Dijon, Bourgogne, France.
Unité Fonctionnelle d'Innovation diagnostique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Marcus Cy Chan (MC)

Department of Paediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong, Hong Kong.

Jasmine Lee-Fong Fung (JL)

Department of Paediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong, Hong Kong.

Megan Rech (M)

Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

Angela Abicht (A)

Medical Genetics Center (MGZ), Munich, Germany.

Marion Aubert Mucca (M)

Department of Medical Genetics, University Hospital Centre Toulouse, Toulouse, Midi-Pyrénées, France.

Jason Carmichael (J)

Department of Medical Genetics and Metabolism, Valley Children's Hospital, Madera, California, USA.

Nicolas Chassaing (N)

Department of Medical Genetics, University Hospital Centre Toulouse, Toulouse, Midi-Pyrénées, France.

Robin Clark (R)

Pediatrics Specialty Clinics, Loma Linda University Medical Center, Loma Linda, California, USA.

Christine Coubes (C)

Department of Medical Genetics, University Hospital Center Montpellier, Montpellier, Languedoc-Roussillon, France.

Anne-Sophie Denommé-Pichon (AS)

UFR Des Sciences de Santé, INSERM UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Université de Bourgogne, Dijon, Bourgogne, France.
Unité Fonctionnelle d'Innovation diagnostique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

John Karl de Dios (JK)

Department of Medical Genetics, Dayton Children's Hospital, Dayton, Ohio, USA.

Eleina England (E)

Center for Mendelian Genomics and Medical and Population Genetics Program, Broad Institute, Cambridge, Massachusetts, USA.

Benoit Funalot (B)

Department of Clinical Genetics, Hopital Henri Mondor, Creteil, Île-de-France, France.

Marion Gerard (M)

Service de Génétique, Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, France.

Maries Joseph (M)

Department of Medical Genetics and Metabolism, Valley Children's Hospital, Madera, California, USA.

Colleen Kennedy (C)

Department of Medical Genetics and Metabolism, Valley Children's Hospital, Madera, California, USA.

Camille Kumps (C)

Division of Genetic Medicine, Lausanne University Hospital, Lausanne, VD, Switzerland.

Marjolaine Willems (M)

Medical Genetic Department for Rare Diseases and Personalized Medicine, Reference Center AD SOOR, AnDDI-RARE, Groupe DI, Inserm U1298, Montpellier University, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.

Ingrid M B H van de Laar (IMBH)

Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Coranne Aarts-Tesselaar (C)

Department of Pediatrics, Amphia Hospital, Breda, North Brabant, Netherlands.

Marjon van Slegtenhorst (M)

Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Daphné Lehalle (D)

Department of Clinical Genetics, Hopital Henri Mondor, Creteil, Île-de-France, France.

Kathleen Leppig (K)

Genetic Services, Kaiser Permanente Washington, Seattle, Washington, USA.

Lennart Lessmeier (L)

Institute of Human Genetics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.

Lynn S Pais (LS)

Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.

Heather Paterson (H)

Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.

Subhadra Ramanathan (S)

Pediatrics Specialty Clinics, Loma Linda University Medical Center, Loma Linda, California, USA.

Lance H Rodan (LH)

Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.

Andrea Superti-Furga (A)

Division of Genetic Medicine, Lausanne University Hospital, Lausanne, VD, Switzerland.

Brian H Y Chung (BHY)

Department of Paediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong, Hong Kong.

Elliott Sherr (E)

Brain Development Research Program, Department of Neurology, University of California San Francisco Division of Hospital Medicine, San Francisco, California, USA.

Christian Netzer (C)

Institute of Human Genetics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.

Christian P Schaaf (CP)

Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Institute of Human Genetics, Heidelberg University, Heidelberg, Baden-Württemberg, Germany.
Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA.

Florian Erger (F)

Institute of Human Genetics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany florian.erger@uk-koeln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH